Neos Therapeutics Priced, Nasdaq: NEOS

Developing easily swallowed formulations of ADHD treatments.

Industry: Health Care

Latest Trade: $9.75 0.00 (0.0%)

First Day Return: +30.3%

Return from IPO: -35.0%

Industry: Health Care

We are a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing our proprietary modified-release drug delivery technology platform, which we have already used to develop our three branded product candidates for the treatment of attention deficit hyperactivity disorder, or ADHD. Our product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms. Our proprietary modified-release drug delivery platform has enabled us to create novel, extended-release ODT and liquid suspension dosage forms. If approved, we believe our most advanced product candidates, NT-0102 and NT-0202, will be the first methylphenidate XR-ODT and the first amphetamine XR-ODT, respectively, for the treatment of ADHD on the market.
more less
IPO News for Neos Therapeutics
more
IPO Data
IPO File Date 06/19/2015
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.8
Deal Size ($mm) $72
IPO Data
IPO Date 07/22/2015
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.8
Deal Size ($mm) $72
Underwriters
more
Company Data
Headquarters Grand Prairie, TX
Founded 1994
Employees 59
Website www.neostx.com